Alnylam Pharmaceuticals
ALNY
#636
Rank
โ‚น2.734 T
Marketcap
โ‚น21,204
Share price
-1.00%
Change (1 day)
47.39%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2024 : โ‚น110.20 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is โ‚น110.20 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31โ‚น108.67 B-0.53%
2022-12-31โ‚น109.25 B47.13%
2021-12-31โ‚น74.25 B94.8%
2020-12-31โ‚น38.11 B75.93%
2019-12-31โ‚น21.66 B932.85%
2018-12-31โ‚น2.09 B9.51%
2017-12-31โ‚น1.91 B-81.21%
2016-12-31โ‚น10.19 B
2007-12-31โ‚น0.26 B-34.45%
2006-12-31โ‚น0.40 B21.59%
2005-12-31โ‚น0.33 B6.71%
2004-12-31โ‚น0.31 B268.45%
2003-12-31โ‚น84.64 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
โ‚น9.99 B-90.93%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น228.90 B 107.71%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น118.31 B 7.35%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น43.37 B-60.65%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น40.29 M-99.96%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น2.722 T 2,370.29%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น2.155 T 1,855.76%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น1.631 T 1,380.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel